


Although the information submitted herewith may be "material" to the Examiner's consideration of the subject application, this submission is not intended to constitute an admission that such information is "prior art" as to the claimed invention.

In accordance with 37 C.F.R. § 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made.

This Information Disclosure Statement is being filed with this application. Thus, no fee is required. 37 C.F.R. §1.97.

Respectfully submitted,

RATNER & PRESTIA



Robert L. Andersen, Reg. No. 25,771

H. Steve Ngo, Reg. No. 42,932

Attorneys for Applicants

Enclosure: PTO Form 1449

Dated: October 25, 2001

P.O. Box 980

Valley Forge, PA 19482-0980

(610) 407-0700

The Assistant Commissioner for Patents is hereby authorized to charge payment to Deposit Account No. **19-2387** of any fees associated with this communication.

EXPRESS MAIL Mailing Label Number: EL 743 542 246 US
Date of Deposit: October 25, 2001

I hereby certify that this paper and fee are being deposited, under 37 C.F.R. § 1.10 and with sufficient postage, using the "Express Mail Post Office to Addressee" service of the United States Postal Service on the date indicated above and that the deposit is addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.


KATHLEEN LIBBY

FORM PTO-1449 (Rev. 2-32)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. GH-50030-D1	SERIAL NO. To Be Assigned
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		APPLICANT Michael Brigham-Burke, <i>et al.</i>	
		FILING DATE Herewith	
		GROUP To Be Assigned	

 COPY OF PAPERS
 ORIGINALLY FILED

 10/066209
 10/066209

U.S. PATENT DOCUMENTS

Examiner Initial	Document Number	Date	Name	Class	Sub Class	Filing Date
	5,710,019	01/20/98	Li, et al.	435	69.1	06/05/95

FOREIGN PATENT DOCUMENTS

Examiner Initial	Document Number	Date	Country	Class	Sub Class	Translation YES NO
	EP 0 308 378 A2	3/22/89	EPO			
	WO 96/26217	08/29/96	PCT			
	WO 96/28546	9/19/96	PCT			
	WO 96/34095	10/31/96	PCT			
	WO 97/01633	01/16/97	PCT			
	WO 97/23614	07/03/97	PCT			
	WO 97/25428	07/17/97	PCT			
	WO 97/33899	09/18/97	PCT			
	WO 97/34911	09/25/97	PCT			
	WO 98/18824	05/07/98	PCT			

OTHER DOCUMENTS

(Including Author, Title, Date, Pertinent Pages, Etc.)

1.	Ngo, et al., The Protein Folding Problem and Tertiary Structure Prediction, Merz and Le Grand (Eds), August, 1994, Springer Verlag, pp. 433 and 492-495.
2.	Walzak, et al., "TRAIL-R2: a novel apoptosis-mediating receptor for TRAIL", J. EMBO., 16, pp. 5386-5396 (1997).
3.	Simonet, et al., "Osteoprotegerin: a novel secreted protein involved in the regulation of bone density", Cell, 89, pp. 309-319 (1997).
4.	Kwon, et al., "A newly identified member of the tumor necrosis factor receptor etc.", J. Biol. Chem., 272, pp. 14272-14276 (1997).
5.	Marsters, et al., "Herpes Virus entry Mediator, a member of the tumor necrosis factor etc.", J. Biol. Chem., 272, pp. 14029-14032 (1997).
6.	Hsu, et al., "ATAR, a novel tumor necrosis factor receptor family member, etc.", J. Biol. Chem., 272, pp. 13471-13474 (1997).
7.	Pitti, et al., "Induction of apoptosis by Apo-2 ligand, a new member of the tumor etc.", J. Biol. Chem., 271, pp. 12687-12690 (1996).
8.	MacFarlane, et al., "Identification and cloning of two novel receptors for the cytotoxic etc.", J. Biol. Chem., 272, pp. 25417-25420 (1997).
9.	Lacey, et al., "Osteoprotegerin Ligand is a cytokine that regulates osteoclast etc.", Cell, 93, pp. 165-176 (1998).
10.	Mauri, et al., "Light, a new member of the TNF superfamily and lymphotoxin etc.", Immunity, 8, pp. 21-30 (1998).

Examiner	Date Considered
----------	-----------------

Examiner: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449 (Rev. 2-32)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. GH-50030-D1	SERIAL NO. To Be Assigned
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		APPLICANT Michael Brigham-Burke, <i>et al.</i>	
		FILING DATE Herewith	GROUP To Be Assigned

		11.	Degli-Esposito, et al., "Cloning and characterization of TRAIL-R3 etc.", J. Exp. Med., 186, pp. 1165-1170 (1997).
		12.	Yamagucki, et al., "Characterization of Structural Domains of Human Osteoclastogenesis, etc.", J. Biol. Chem., 273, pp. 5117-5123 (1998).
		13.	Pan, et al., "The receptor for the cytotoxoid ligand TRAIL", Science, 276 pp. 111-113 (1997).
		14.	Yasuda, et al., "Identity of Osteoclastogenesis inhibitory factor (OCIF) and etc.", Endocrinology, 139, pp. 1329-1337 (1998).
		15.	Schneider, et al., "TRAIL receptors 1 (DR4) and 2 (DR5) signal FADD-dependent etc.", Immunity, 7, pp. 831-836 (1997).
		16.	Chaudhary, et al., "Death receptor 5, a new member of the TNFR family and DR4 induce etc.", Immunity, 7, pp. 821-830 (1997).
		17.	Degli-Esposito, et al., "The novel receptor TRAIL-R3 induces NF-kB and protects against etc.", Immunity, 7, pp. 813-820 (1997).
		18.	Wiley, et al., "Identification and characterization of a new member of the TNF etc.", Immunity, 3, pp. 673-682 (1995).
		19.	Montgomery, et al., "Herpes Simplex Virus-1 Entry into cells mediated by a novel member, etc.", Cell, 87, pp. 427-436 (1996).
		20.	Sheridan, et al., "Control of TRAIL-induced apoptosis by a family of signaling and decoy etc.", Science, 277 pp. 818-821 (1997).
		21.	Pan et al., "An antagonist decoy receptor and a death domain containing etc.", Science, 277, pp. 815-818 (1997).
		22.	Yasuda, et al., "Osteoclast differentiation factor is a ligand for osteoprotegerin etc.", Proc. Natl. Acad. Sci. USA, Natl. Acad. Sci USA, 95, pp. 3597-3602 (1998).
		23.	Emery et al., "Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL", J. Biol. Chem., 273, pp. 14363-14367 (1998).

Examiner	Date Considered
----------	-----------------

Examiner: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.